<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354978</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0614</org_study_id>
    <nct_id>NCT00354978</nct_id>
  </id_info>
  <brief_title>Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients</brief_title>
  <official_title>Phase II Study of Irinotecan, Leucovorin, 5-Fluorouracil (FOLFIRI) Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

        1. To estimate progression-free survival (PFS) at 12 months in subjects with metastatic
           colorectal cancer who receive FOLFIRI [folinic acid (leucovorin or LV), 5-Fluorouracil
           (5-FU), irinotecan) plus bevacizumab as first line treatment.

        2. To determine the objective response rate and the duration of objective response in this
           population.

        3. To assess overall survival (OS) in this population.

        4. To measure the effect of treatment on intratumoral blood volume and microvascular
           permeability by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in
           consenting patients in whom it is technically feasible.

        5. To correlate plasma proteomics with response.

        6. To assess the safety of this regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer growth may be affected by a protein in the body called &quot;vascular
      endothelial growth factor&quot; (VEGF). A drug that blocks VEGF may be an effective treatment for
      colorectal cancer. Bevacizumab is designed to block VEGF. Bevacizumab will be added to
      5-Fluorouracil (5-FU), leucovorin (LV), and irinotecan, a drug combination routinely used in
      the treatment of advanced colorectal cancer.

      Before you can start treatment on the study, you will have what are called &quot;screening tests&quot;.
      These tests will help the doctor decide if you are eligible to take part in the study. You
      will be asked questions about your medical history and about any medications you are
      currently taking or have taken in the past. You will have a complete physical exam and your
      heart rate, temperature, breathing rate, blood pressure, height, and weight will be measured.
      You will be asked about your ability to perform every day activities. You will have an
      electrocardiogram (ECG - a test that measures the electrical activity of the heart). You will
      have a chest x-ray and scans (either computed tomography (CT) or magnetic resonance imaging
      (MRI)) of your abdomen and pelvis to evaluate the cancer. Scans of other parts of your body
      also may be taken if your doctor thinks they are needed to evaluate your cancer. Blood (about
      3 tablespoons) and urine samples will be collected for routine tests, including complete
      blood count, carcinoembryonic antigen (CEA) level (a marker for your cancer), and chemistry
      profile. Women who are able to have children must have a negative blood or urine pregnancy
      test

      If the screening evaluations show you are eligible to take part in the study, you may begin
      treatment Study treatment is repeated every 2 weeks (14 days). Each 14-day period of
      treatment is called a &quot;cycle&quot; of therapy. You must receive study treatment at M. D. Anderson.

      All study drugs will be given through a needle into a vein. For your first treatment, you
      will receive bevacizumab alone first. The first dose of bevacizumab will be given over about
      90 minutes. If you do not have a reaction (such as fever/chills), the next dose will be given
      over about 60 minutes, and if again no reaction occurs, each dose after that will be given
      over about 30 minutes. If you experience a reaction to the bevacizumab infusion, you may be
      given acetaminophen (such as Tylenol) by mouth and/or an antihistamine by vein over 30
      minutes before each dose to help decrease the risk of further reactions.

      Fourteen (14) days later and for all future cycles, you will receive bevacizumab, LV, and
      irinotecan given on Day 1 of each cycle. 5-FU is given over 46 hours over Days 1-3.

      Bevacizumab will be given as described above. When the bevacizumab infusion ends, you will
      receive LV and irinotecan, starting at the same time. You will receive irinotecan over 90
      minutes and LV over 2 hours. When the LV infusion ends, 5-FU will be given over 2 to 4
      minutes. This is followed by more 5-FU given over 46 hours using a small portable pump (about
      the size of a standard paperback book).

      Before each new cycle of study treatment, you will be asked questions about any side effects
      you may have had and about any medications you are currently taking or have taken since you
      last saw the study doctor. You will have a complete physical exam, including measurements of
      blood pressure, pulse, temperature, and weight. You will be asked about your ability to
      perform every day tasks. About 3 tablespoons of blood will be taken for routine laboratory
      tests. These tests include a complete blood count and chemistry profile. A urine sample will
      be taken before every other cycle of treatment. During the first cycle of treatment, on Day
      8, you will have a sample of blood (about 3 teaspoons) drawn. This test may be done at a lab
      close to your home.

      You will also have either CT scans or MRI of the tumor(s) every 8 weeks and at the end of the
      study treatment. About 1 tablespoon of blood will be taken to check your CEA level at the
      same time scans are done. Additional tests may be done during the study if your doctor feels
      it is necessary for your care. Except for the weekly blood test, which may be done at a lab
      close to home, all testing and evaluations must be done at M. D. Anderson.

      If you experience severe side effects, treatment may be delayed, stopped, or you may receive
      smaller doses of the treatment. You may continue to receive study treatment unless the
      disease gets worse, you decide not to take part any longer, or your doctor decides it is in
      your best interest to stop treatment.

      When you stop study treatment, you will be asked to have some tests and evaluations done at
      an end of study visit. Urine and about 3 tablespoons of blood will be taken for routine
      laboratory tests, including complete blood count, CEA level, and chemistry profile. You will
      also have a physical exam. CT scan or MRI scan of your abdomen and pelvis will also be done
      to check the size and location of your disease.

      Once you stop receiving study treatment, the study doctor or nurse will continue to check how
      you are doing, either in the clinic or by telephone if you stop coming to M. D. Anderson,
      every 3 months for the rest of your life.

      This is an investigational study. The drugs used in this study are approved by the FDA for
      treatment of advanced colorectal cancer. Up to 43 patients will take part in this multicenter
      study. About 38 will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression-free Survival (PFS)</measure>
    <time_frame>From baseline until first documented progression or death from any cause, whichever came first, assessed up to 75 months</time_frame>
    <description>PFS is defined as the duration of time from start of treatment to time of disease progression using Kaplan-Meier median PFS time.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFIRI plus Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>400 mg/m^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.
2.4 g/m^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m^2 injection.</description>
    <arm_group_label>FOLFIRI plus Bevacizumab</arm_group_label>
    <other_name>F of FOLFIRI</other_name>
    <other_name>5-FU</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Efudex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.
5 mg/kg by vein on Day 1 of 14 day cycle.</description>
    <arm_group_label>FOLFIRI plus Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
    <other_name>Anti-VEGF monoclonal antibody</other_name>
    <other_name>rhuMAb-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>400 mg/m^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.</description>
    <arm_group_label>FOLFIRI plus Bevacizumab</arm_group_label>
    <other_name>FOL of FOLFIRI</other_name>
    <other_name>LV</other_name>
    <other_name>folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m^2 by vein over 90 minutes on Day 1 of 14 day cycle.</description>
    <arm_group_label>FOLFIRI plus Bevacizumab</arm_group_label>
    <other_name>IRI of FOLFIRI</other_name>
    <other_name>CPT-11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient must have histologically or cytologically confirmed colorectal adenocarcinoma
             with metastatic disease documented on diagnostic imaging studies.

          2. Patient must have measurable lesions as defined by modified Response Evaluation
             Criteria In Solid Tumors (RECIST) criteria. Patients who agree to undergo the optional
             Dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) studies must have a
             metastatic liver lesion that is &gt; 2 cm.

          3. Patient has not previously received chemotherapy for metastatic disease.

          4. Patient may have received adjuvant therapy for primary colorectal cancer provided that
             at least 6 months have elapsed from the time the adjuvant therapy was concluded and
             recurrent disease was documented.

          5. Written informed consent obtained.

          6. Age greater than/equal to 18 years.

          7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          8. Patients must have adequate organ and marrow function as defined below: Â· Absolute
             neutrophil count (ANC) greater than/equal to 1,500/mm3; platelets greater than/equal
             to 100,000/ mm3; hemoglobin greater than/equal to 9 gm/dL (may be transfused to
             maintain or exceed this level); total bilirubin less than/equal to 1.5 within
             institutional upper limit of normal (IULN); aspartate aminotransferase (AST or
             SGOT)/alanine aminotransferase (ALT or SGPT) less than/equal to 2.5 times IULN, or
             less than/equal to 5 times IULN if known liver metastases; serum creatinine less
             than/equal to 1.5 times IULN

          9. Patients must have an International Normalized Ratio (INR) less than/equal to 1.5 and
             a Partial thromboplastin time (PTT) less than/equal to IULN

         10. Patients with history of hypertension must be well-controlled (blood pressure less
             than/equal to 150/100), on a stable regimen of anti-hypertensive therapy.

        Exclusion Criteria:

          1. Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental therapeutic drug study other than this protocol.

          2. Prior full field radiotherapy less than/equal to 4 weeks or limited field radiotherapy
             less than/equal to 2 weeks prior to treatment.

          3. History or presence of central nervous system metastases.

          4. Female patients who are pregnant or lactating or men and women of reproductive
             potential not willing to employ an effective method of birth control during treatment
             and for 3 months after discontinuing study treatment.

          5. A history of prior treatment with bevacizumab or other agents targeting Vascular
             endothelial growth factor (VEGF).

          6. Known dihydropyrimidine dehydrogenase deficiency.

          7. Patients with a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to bevacizumab, irinotecan, 5-FU, or leucovorin.

          8. Serious non-healing wound, ulcer, or active bone fracture.

          9. Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to Day 0; anticipation of need for major surgical procedure during the course of
             the study.

         10. Fine needle aspirations or core biopsies within 7days prior to Day 0.

         11. For patients who agree to Optional DCE-MRI studies: Cardiac pacemaker,
             neurostimulator, metal implants other than those specifically approved as safe for use
             in MR scanners at the magnetic field strength used for these studies, claustrophobia,
             obesity (weight exceeding equipment limits).

         12. Current or recent use of full-dose warfarin (except as required to maintain patency of
             preexisting, permanent indwelling IV catheters) for subjects receiving warfarin, INR
             should be &lt; 1.5). Patients may have prophylactic use of low molecular weight heparin,
             however therapeutic use of heparin or low molecular weight heparin is not acceptable.

         13. Evidence of bleeding diathesis or coagulopathy.

         14. Patients with a history of another primary malignancy less than/equal to 5 years, with
             the exception of non-melanoma skin cancer, and carcinoma in situ of uterine cervix.

         15. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 0, unless affected area has been removed surgically.

         16. Any of the following concurrent severe and/or uncontrolled medical conditions which
             could compromise participation in the study: Uncontrolled high blood pressure, history
             of labile hypertension, or history of poor compliance with an antihypertensive
             regimen; Unstable angina; New York Heart Association (NYHA) greater than/equal to
             grade 2 congestive heart failure

         17. Myocardial infarction within 6 months of study enrollment; History of stroke within 6
             months of study enrollment; Unstable symptomatic arrhythmia requiring medication
             (Patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal
             supraventricular tachycardia are eligible); Clinically significant peripheral vascular
             disease; Uncontrolled diabetes; Serious active or uncontrolled infection

         18. History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that might affect the
             interpretation of the results of the study or render the subject at high risk from
             treatment complications.

         19. Inability to comply with study and/or follow-up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Kopetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lyndon Baines Johnson General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2006</study_first_submitted>
  <study_first_submitted_qc>July 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <results_first_submitted>June 14, 2011</results_first_submitted>
  <results_first_submitted_qc>September 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2011</results_first_posted>
  <last_update_submitted>September 14, 2011</last_update_submitted>
  <last_update_submitted_qc>September 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>CPT-11</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>LV</keyword>
  <keyword>Folinic Acid</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>5-FU</keyword>
  <keyword>Adrucil</keyword>
  <keyword>Efudex</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Avastin</keyword>
  <keyword>Anti-VEGF monoclonal antibody</keyword>
  <keyword>rhuMAb-VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: January 13, 2005 through January 31, 2007. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Forty nine (49) patients were enrolled onto the study, and 6 patients did not meet inclusion criteria and were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FOLFIRI Plus Bevacizumab</title>
          <description>FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FOLFIRI Plus Bevacizumab</title>
          <description>FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="26" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Progression-free Survival (PFS)</title>
        <description>PFS is defined as the duration of time from start of treatment to time of disease progression using Kaplan-Meier median PFS time.</description>
        <time_frame>From baseline until first documented progression or death from any cause, whichever came first, assessed up to 75 months</time_frame>
        <population>Analysis per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI Plus Bevacizumab</title>
            <description>FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival (PFS)</title>
          <description>PFS is defined as the duration of time from start of treatment to time of disease progression using Kaplan-Meier median PFS time.</description>
          <population>Analysis per protocol.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread=".02" lower_limit="9.6" upper_limit="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years and 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FOLFIRI Plus Bevacizumab</title>
          <description>FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watery Eye</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hemorrhage (Rectum)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Mucositis (Oral Cavity)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Neuropathy (Sensory)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain (Muscle)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Serum Glutamic Oxaloacetic Transaminase (AST)</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT,SGPT (Serum Glutamic Pyruvic Transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Neutrophils/Granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Pulmonary (Nose)</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pulmonary (Other)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hand-Foot Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis (Embolism)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Kopetz, MD Associate Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-2828</phone>
      <email>mjlim@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

